Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation.
نویسندگان
چکیده
WE PREVIOUSLY reponed our experience of infectiOUS complications occurring following liver transplantation (OLT) under an experimental immunosuppressive agent FK 506. I In February 1990 we initiated a randomized trial comparing this new drug to cyclosporine (eyA) in patients undergoing their first OLT. In this repon we analyzed the infectious complications in the first 110 patients enrolled in this study.
منابع مشابه
Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine.
THE USE of cyclosporine (CyA) has greatly impacted the success of liver transplantation. FK 506 is a newly described immunosuppressive agent, with mechanisms of action similar to those of Cy A, but more potent on a weight-ta-weight basis. Pilot studies of FK 506 in primary liver transplantation have shown encouraging results. 1 A randomized trial using FK 506 with low-dose steroids (LDS) was co...
متن کاملInfections in adult liver transplant patients under FK 506 immunosuppression.
THE preliminary results of infectious complications in orthotopic liver transplantation IOLT) using FK 506 as a primary immunosuppressive agent were encouraging. I This early experience. however. was limited to only 20 patients who were followed for a short period of time. We have now extended our observations to 110 consecutive adult liver transplant recipients of first livers enrolled in the ...
متن کاملSingle-center experience with primary orthotopic liver transplantation with FK 506 immunosuppression.
OBJECTIVE The efficacy for primary orthotopic liver transplantation of a new immunosuppressive agent, FK 506 (tacrolimus, Prograf, Fujisawa USA, Deerfield, IL), was determined. SUMMARY BACKGROUND DATA After 3 years of preclinical research, a clinical trial of FK 506 for orthotopic liver transplantation was begun in February 1989, first as a rescue therapy for patients with intractable rejecti...
متن کاملConversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.
WITH the use of Cy A for clinical liver transplantation, I-year survival rates have approached 70%. Nevertheless, allograft rejection continues to be the most common cause of retransplantation and death. Clinical rejection occurs in 70% ofliver allograft recipients on CyA and steroid therapy. 1 In addition, nephrotoxicity is the principal and dose-limiting side effect of Cy A. Chronic renal dam...
متن کاملOne thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.
FK 506 (Tanolimus. Prograf'") has been recently approved by the Food and Drug Administration (FDA) for baseline immunosuppression following orthotopic liver transplantation (OLT). The drug was first used clinically in 1989. 1 and I year later at the Thirteenth International Congress of Transplantation Society. San Francisco. CA 1990. extensive reports were given from our center describing the p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Transplantation proceedings
دوره 24 1 شماره
صفحات -
تاریخ انتشار 1992